Does orphan drug legislation really answer the needs of patients?
Office of Orphan Products Development, Food and Drug Administration, Amgen, Washington, DC, USA.
Marlene E
ME
Haffner
Josep
J
Torrent-Farnell
Paul D
PD
Maher
D005062:European Union; D006301:Health Services Needs and Demand; D006801:Humans; D009042:Motivation; D009965:Orphan Drug Production / Q000191:economics / Q000331:legislation & jurisprudence*; D035583:Rare Diseases / Q000188:drug therapy*; D014481:United States